ABOS Acumen Pharmaceuticals, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ABOS matters now
Acumen Pharmaceuticals, Inc. (ABOS) is a US stock in Healthcare. The latest InvestLog snapshot shows $2.63 with -2.59% on the session and $159.3M in market capitalization; recent performance reads 1-month +4.15% and YTD +7.11%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-20.7M, and EPS of $-0.33. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -77.1%.
The latest indexable market news headline is "Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC®) 2026" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $7.00; recent insider activity includes Porter Derrell filing M-Exempt. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.63
P/S
0.00
EV/EBITDA
-1.07
DCF Value
$0.38
FCF Yield
-77.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-123.1%
ROA
-84.8%
ROIC
-96.5%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-20.7M | $-0.33 |
| Q4 2025 | $0.00 | $-25.1M | $-0.42 |
| FY 2025 | $0.00 | $-121.3M | $-2.00 |
| Q3 2025 | $0.00 | $-26.5M | $-0.44 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$7.00
Target (Median)
$7.00
Target Range
$7.00 - $7.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.35
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.